AbbVie steps into the obesity drug race, licensing medicine from Danish firm

The obesity medicine field has gained a new entrant, with AbbVie on Monday announcing it had licensed an experimental weight loss drug from a Danish company that is in a Phase 1 trial.

The deal includes a $350 million upfront payment to the company, Gubra, for the rights to its drug, called for now GUB014295. AbbVie will pay up to some $1.9 billion if certain development and sales milestones are met.

The agreement comes less than a year since Robert Michael took over as CEO of AbbVie and as the company looks for its next top-selling drugs following the loss of patent protection for its mega blockbuster autoimmune treatment Humira. In a statement, Michael said that the Gubra partnership offers “a compelling opportunity based on the potential to address patient needs while also fostering long-term growth for our company.”

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

ArriVent outlines plans for $135M IPO in second biotech listing of 2024

ArriVent Biopharma, a Pennsylvania drugmaker developing a China-approved cancer treatment for the US and other geographies, plans to raise net proceeds of about $135 million

January 23, 2024

Pfizer’s bet on gene therapies in haemophilia has been a bust

Pfizer has ended the global commercialisation of its haemophilia B (factor IX deficiency) gene therapy Beqvez, citing soft demand for gene therapies among haemophilia patients

February 27, 2025

Study finds that MRI is more sensitive than PSA test for detecting prostate cancer

The recent BMJ Oncology study finds that using MRI screenings based on age can effectively identify prostate cancer risks independent of traditional PSA levels. The

August 28, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.